Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Some patients dropped out of the trial early because they had lost so much weight.

Doctors say the class of medications that includes Ozempic and Zepbound still offers health benefits for people with diabetes ...

Dec 11 () - Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ​late-stage trial, outperforming its blockbuster drug Zepbound and ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

Eli Lilly CEO David Ricks has announced a new $6 billion manufacturing plant in Alabama dedicated to producing the company's ...

Tan France is using his experience in fashion way beyond styling. Now, the Queer Eye staple is partnering with Lilly, the makers of Zepbound, for the Changing the Thread Collection™, the first ...

LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...